Literature DB >> 8388198

Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers.

J A Barone1, J G Koh, R H Bierman, J L Colaizzi, K A Swanson, M C Gaffar, B L Moskovitz, W Mechlinski, V Van de Velde.   

Abstract

The influence of food on itraconazole pharmacokinetics was evaluated for 27 healthy male volunteers in a single-dose (200 mg) crossover study with capsules containing itraconazole-coated sugar spheres. This study was followed by a study of the steady-state pharmacokinetics for the same subjects with 15 days of administration of itraconazole at 200 mg every 12 h. Concentrations of itraconazole and hydroxyitraconazole, the active main metabolite, were measured in plasma by high-performance liquid chromatography. The results of the food interaction segment showed that a meal significantly enhances the amount of itraconazole absorbed. The mean maximum concentration in plasma of unmetabolized itraconazole after fasting (140 ng/ml) was about 59% that after the standard meal (239 ng/ml). The rate of elimination was not affected (terminal half-life, approximately 21 h). The mean maximum concentration in plasma of hydroxyitraconazole after fasting was about 72% the postmeal concentration (287 and 397 ng/ml, respectively). The terminal half-life of hydroxyitraconazole was approximately 12 h. Steady-state concentrations of itraconazole and hydroxyitraconazole were reached after 14 or 15 days of daily dosing. The average steady-state concentrations were approximately 1,900 ng/ml for itraconazole and 3,200 ng/ml for hydroxyitraconazole. The shape of the elimination curve for itraconazole after the last dose was indicative of saturable elimination. This conclusion was confirmed by the sevenfold increase in the area under the curve from 0 to 12 h at steady state compared with the area under the curve from 0 h to infinity after a single dose. It was furthermore confirmed by the larger-than-expected number of half-lives required to achieve steady-state plasma drug levels.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8388198      PMCID: PMC187759          DOI: 10.1128/AAC.37.4.778

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  THE TWO-PERIOD CHANGE-OVER DESIGN AN ITS USE IN CLINICAL TRIALS.

Authors:  J E GRIZZLE
Journal:  Biometrics       Date:  1965-06       Impact factor: 2.571

2.  The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects.

Authors:  A Van Peer; R Woestenborghs; J Heykants; R Gasparini; G Gauwenbergh
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography.

Authors:  R Woestenborghs; W Lorreyne; J Heykants
Journal:  J Chromatogr       Date:  1987-01-23

4.  A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.

Authors:  D J Schuirmann
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

5.  Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results.

Authors:  B Dupont; E Drouhet
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

Review 6.  The triazole antifungal agents: a review of itraconazole and fluconazole.

Authors:  E M Bailey; D J Krakovsky; M J Rybak
Journal:  Pharmacotherapy       Date:  1990       Impact factor: 4.705

Review 7.  The clinical pharmacokinetics of itraconazole: an overview.

Authors:  J Heykants; A Van Peer; V Van de Velde; P Van Rooy; W Meuldermans; K Lavrijsen; R Woestenborghs; J Van Cutsem; G Cauwenbergh
Journal:  Mycoses       Date:  1989       Impact factor: 4.377

Review 8.  Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

9.  Nonlinear pharmacokinetics of the new positive inotropic agent sulmazole in the dog.

Authors:  E R Garrett; W Roth
Journal:  J Pharm Sci       Date:  1983-02       Impact factor: 3.534

10.  Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole.

Authors:  D W Warnock; A Turner; J Burke
Journal:  J Antimicrob Chemother       Date:  1988-01       Impact factor: 5.790

View more
  52 in total

Review 1.  Triazole antifungal agents in invasive fungal infections: a comparative review.

Authors:  Cornelia Lass-Flörl
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

Review 2.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma.

Authors:  Lorena Baietto; Antonio D'Avolio; Giusi Ventimiglia; Francesco Giuseppe De Rosa; Marco Siccardi; Marco Simiele; Mauro Sciandra; Giovanni Di Perri
Journal:  Antimicrob Agents Chemother       Date:  2010-06-07       Impact factor: 5.191

4.  Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients.

Authors:  Timothy H Waterhouse; Stefanie Redmann; Stephen B Duffull; John A Eccleston
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

5.  A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients.

Authors:  Stefanie Hennig; Timothy H Waterhouse; Scott C Bell; Megan France; Claire E Wainwright; Hugh Miller; Bruce G Charles; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2006-10-30       Impact factor: 4.335

6.  Limited-sampling strategy models for itraconazole and hydroxy-itraconazole based on data from a bioequivalence study.

Authors:  G Suarez-Kurtz; F A Bozza; F L Vicente; C G Ponte; C J Struchiner
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

7.  Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers.

Authors:  J A Barone; B L Moskovitz; J Guarnieri; A E Hassell; J L Colaizzi; R H Bierman; L Jessen
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

8.  Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.

Authors:  Gopal Krishna; Allen Moton; Lei Ma; Matthew M Medlock; James McLeod
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

9.  A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation.

Authors:  Marta Valle; Enrico Di Salle; Maria Gabriella Jannuzzo; Italo Poggesi; Maurizio Rocchetti; Riccardo Spinelli; Davide Verotta
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

10.  Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Marina McIver; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.